^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IDO/TDO dual inhibitor

i
Other names: IDO/TDO dual inhibitor
Associations
Trials
Company:
Lumos Pharma
Drug class:
IDO inhibitor, Tryptophan 2,3-dioxygenase inhibitor
Associations
Trials
over4years
Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients. (PubMed, Int J Sports Med)
IL-6 levels decreased over the first three months for both intervention groups as well as the Control group (Supervised: p < 0.01, Home-based: p < 0.010, Control group: p < 0.01). Supervised resistance exercise might positively regulate the Kynurenine pathway and downregulate the kynurenine/tryptophan (indicative of IDO/TDO enzyme) levels, hence modulating the immune system.
Clinical • Journal
|
IL6 (Interleukin 6)
|
IDO/TDO dual inhibitor
over4years
[VIRTUAL] Metabolomic adaptations and correlates of survival to immune checkpoint blockade (AACR-II 2020)
To investigate the generalizability of our results, we also performed metabolomics and serum specimens from a large randomized Phase 3 trial (CheckMate 025) with 743 RCC patients, among which 394 received nivolumab and 349 received everolimus. We identified increased tryptophan to kynurenine conversion in response to PD1 blockade in a subset of melanoma and RCC patients. By using independent cohorts, we showed that Kyn/Trp temporal alterations robustly correlated with overall survival of patients receiving nivolumab. Our findings illustrate that checkpoint blockade in combination with IDO/TDO inhibitors might only benefit a selected group of patients with checkpoint-inhibition-triggered kynurenine pathway activation.
Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • IDO1 (Indoleamine 2,3-dioxygenase 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • everolimus • Dual TDO/IDO Inhibitor • IDO/TDO dual inhibitor
over4years
[VIRTUAL] Metabolomic adaptations and correlates of survival to immune checkpoint blockade (AACR 2020)
To investigate the generalizability of our results, we also performed metabolomics and serum specimens from a large randomized Phase 3 trial (CheckMate 025) with 743 RCC patients, among which 394 received nivolumab and 349 received everolimus. We identified increased tryptophan to kynurenine conversion in response to PD1 blockade in a subset of melanoma and RCC patients. By using independent cohorts, we showed that Kyn/Trp temporal alterations robustly correlated with overall survival of patients receiving nivolumab. Our findings illustrate that checkpoint blockade in combination with IDO/TDO inhibitors might only benefit a selected group of patients with checkpoint-inhibition-triggered kynurenine pathway activation.
Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • IDO1 (Indoleamine 2,3-dioxygenase 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • everolimus • Dual TDO/IDO Inhibitor • IDO/TDO dual inhibitor